Bank Of America Corp Rain Therapeutics Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.22 $10,355 - $15,040	12,328 Added 178.77%	19,224 $23,000
Q2 2023 Aug 14, 2023	SELL	$1.09 - $9.93 $9,015 - $82,131	-8,271 Reduced 54.53%	6,896 $8,000
Q1 2023 May 12, 2023	BUY	$7.77 - $12.47 $84,125 - $135,012	10,827 Added 249.47%	15,167 $132,000
Q4 2022 Feb 10, 2023	SELL	$5.52 - $8.48 $84,875 - $130,388	-15,376 Reduced 77.99%	4,340 $34,000
Q3 2022 Nov 14, 2022	SELL	$4.75 - $8.01 $97,223 - $163,948	-20,468 Reduced 50.94%	19,716 $96,000
Q2 2022 Aug 12, 2022	SELL	$2.21 - $5.56 $42,889 - $107,902	-19,407 Reduced 32.57%	40,184 $223,000
Q1 2022 May 16, 2022	BUY	$5.07 - $13.68 $12,705 - $34,282	2,506 Added 4.39%	59,591 $302,000
Q4 2021 Feb 08, 2022	BUY	$11.91 - $17.0 $198,968 - $284,002	16,706 Added 41.37%	57,085 $735,000
Q3 2021 Nov 15, 2021	BUY	$13.21 - $20.91 $518,347 - $820,487	39,239 Added 3442.02%	40,379 $604,000
Q2 2021 Sep 13, 2021	BUY	$15.08 - $20.3 $17,191 - $23,142	1,140 New	1,140 $18,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.